KLRK1 and neoplasm: To harness NK cell-mediated toxicity, chimeric receptors linking NKG2D to the cytoplasmic domain of CD3ζ have been constructed, and T cells equipped with such an NKG2D receptor display anti-tumor reactivity in both hematological and solid tumor models [30].